К основному контенту

Men who are victims of domestic violence find it hard to get help and the support they need, British researchers report.

"While both men and women are reluctant to seek professional help for their abuse, there is an added barrier for men voiced in these studies, that they may be falsely accused of being the perpetrator. The men also raised wider concerns about masculinity," said study co-author Dr. Gene Feder, a professor of primary care at the University of Bristol.


He and his colleagues reviewed studies of men in heterosexual and gay relationships.

They found that fears of not being believed or being accused of abuse were factors in not seeking help. Embarrassment and feeling "less of a man" were reported to be other barriers.

Men also worried about their partner and damaging their relationship as well as losing contact with their children. Still others were afraid of telling their family or friends, or getting professional help.

Many men didn't know that professional help was available, the study found, or thought that support services were for women only.

Some men only sought help when their situation became a crisis, the study found.

Those who decided to get help said confidentiality was important, as was seeing the same person over time and not being judged. Men preferred getting help from a woman.

"Our review has revealed that the experience of many men who are victims of domestic abuse is similar to those of women," Feder said in a university news release. "Like women, although male victims wanted the violence to stop, they did not necessarily want to end the relationship."

Domestic violence can have serious consequences on health and well-being. Researchers advise men who are being abused by a partner to seek help first from their primary care doctor, who can connect them with specialized services.

The report was published online June 12 in the journal BMJ Open.

Комментарии

Популярные сообщения из этого блога

A healthy diet may trigger a better response to a certain kind of melanoma treatment. How?

New research suggests that a diet that's full of fiber appears to lead to more diverse intestinal bacteria (microbiome). In turn, a thriving gut microbiome is linked to a stronger response to an immune therapy for the aggressive skin cancer. "We found that patients eating a high-fiber diet at the start of therapy were about five times more likely to respond to the anti-PD-1 immunotherapy," said study author Christine Spencer. She's a research scientist with the Parker Institute for Cancer Immunotherapy in San Francisco. Anti-PD-1 immunotherapy helps the immune system recognize cancer cells as dangerous cells that need to be destroyed, according to the American Cancer Society (ACS). The cancer drugs Keytruda and Opdivo are examples of this type of immunotherapy. Melanoma is a type of skin cancer. It only accounts for about 1 percent of all skin cancers, but is responsible for most skin cancer deaths, the ACS says. Several recent studies have suggested that a ...

American Heart Association News

On Feb. 1, 1961, twins Debbie and Donna Horst arrived at the White House to fanfare. The 6-year-olds, decked out in fancy dresses and satin sashes, found themselves surrounded by a pressing crowd and a sea of blinding flashbulbs as they made their way to see Jacqueline Kennedy. The girls -- both born with holes in their aortas -- were meeting with the first lady to kick off a national campaign to raise awareness about congenital heart defects. "There were hundreds of reporters because this was Jacqueline Kennedy' first public act as first lady," Debbie said. She recalls being startled when the reporters asked Mrs. Kennedy if they could move in closer. "It was frightening because they all jumped at us at once." The Pennsylvania twins, just a few weeks from turning 7, were among the first "Heart Fund Sweethearts" in the campaign to raise money as well as awareness. The month before, they'd met up with Micki and Patricia Gane, also of Pennsylvania...

Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Low-Dose

Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Low-Dose Contraceptive Patch, Twirla PRINCETON, N.J., May 17, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration (FDA) the NDA for its lead product candidate, Twirla®, an investigational low-dose combined hormonal contraceptive patch (AG200-15).  Agile resubmitted the NDA in response to a December 2017 Complete Response Letter (CRL) from the FDA, which identified deficiencies relating to (i) quality control adhesion test methods for the Twirla manufacturing process, (ii) observations identified during an inspection of a facility of our third-party manufacturer for the Twirla NDA that must be resolved, and (iii) questions on the in vivo adhesion properties of Twirla and their potential relationship to the SECURE clinical trial results. The resubmitted NDA includes the results from a...